Next-Generation Sequencing Superior MRD Detection Capabilities with New Myeloid MRD Panel

OGT recently announced the North American launch of its new next-generation sequencing (NGS) Sureseq Myeloid MRD Panel, which provides a flexible NGS workflow for the detection of ultra-low frequency measurable residual disease (MRD)-associated biomarkers in acute myeloid leukemia (AML).

This ultra-sensitive NGS panel leverages OGT’s expertise in hybrid capture to enhance the detection of the largest and most complex AML associated variants in key genes, such as large FLT3-ITDs, that often go undetected by previous generations of PCR-based enrichment technologies, shares the company.

The ultra-sensitive detection of MRD in AML is a critical tool for advancing clinical research in AML. NGS-based AML MRD is being more widely adopted in drug development and studies aiming to improve clinical management of AML. Clinical research studies into MRD continue to drive deeper understanding of AML remission and relapse, including evidence highlighting that MRD negativity is associated with a better 5-year survival rate compared to MRD positive defined samples. Being able to sensitively detect even a few residual leukemic cells provides a more comprehensive picture of the current AML status of a sample.

OGT’s new highly targeted Sureseq Myeloid MRD Panel enables the detection of 13 key AML MRD-associated biomarkers. Key targets include very large, ultra-low frequency FLT3-ITDs (even up to 300 bp) that are traditionally challenging to detect. This streamlined, guideline-driven panel content expands on OGT customer’s MRD detection capabilities to deliver a better understanding of the current AML status, and ensures genomic insights are not missed, opines the firm. Customers can also effortlessly adapt NGS workflows to meet all their sensitivity, sample batching and sequencing requirements - by selecting from a range of pre-optimized workflows, users benefit from the unmatched flexibility of this new NGS MRD panel.

OGT specializes in the development of superior hybrid capture technology that excels in the detection of complex structural variants and eliminates inaccurate calls caused by alternative PCR-based approaches. By employing OGT’s unparalleled bait design process, informed by the team’s unique expertise, the company has developed the Sureseq Myeloid MRD Panel to offer enhanced and reliable, superior detection.

The firm knows how important MRD detection is, and will continue to be, in AML. Advances in the understanding of AML MRD, such as recent research studies highlighting the prognostic ability of FLT3-ITD detection to ascertain the disease course for patients with AML pre- and post-HSCT, emphasize the need for sensitive NGS-based tools to be able to characterize this, and other, key variants in clinical research, mentions the company.

OGT is proud to have developed its newest NGS panel that allows customers to detect key AML-relevant biomarkers, including NPM1 and FLT3-ITDs, at extremely low levels. With its complimentary software, Interpret, which provides an “out-of-the box” bioinformatics pipeline that can be tailored to customers specific requirements, the firm ensures its customers secure the most valuable insights from their MRD data.

(ID:50378795)